Dealbreaker on MSN

Eli Lilly boosts its immunology drug pipeline with $1.2B Ventyx Bio acquisition

Eli Lilly said Ventyx’s pipeline has potential applications in cardiometabolic health, neurodegeneration, and autoimmunity.
BioPharma Dive

Lilly snaps up Ventyx for $1.2B in pursuit of oral immune drugs

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment ...

Monte Rosa's Experimental Drug Slashes Inflammation Linked To Heart Disease

Clinical-stage biotechnology company Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) on Wednesday revealed interim data from an ...
BioWorld

Kangbaida Biotechnology patents new pyroptosis and NLRP3 inflammasome inhibitors

Biotechnology Co. Ltd. has disclosed pyroptosis and NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, type 1 diabetes, gout, inflammatory disorders, multiple sclerosis, ...
The Silicon Review

Eli Lilly Acquires Ventyx for $1.2B in Oral Immunology Bet

Eli Lilly buys Ventyx Biosciences for $1.2B, targeting oral NLRP3 inflammasome inhibitors to expand its immunology pipeline ...
Nature

The NLRP3 inflammasome in acute myocardial infarction

The inflammasome is a macromolecular structure in the cell responsible for sensing danger and triggering a local or systemic inflammatory response Upon activation, the inflammasome produces large ...
BioWorld

Cardio works out for Monte Rosa in NEK7 phase I

Monte Rosa Therapeutics Inc. followed up December’s positive prostate cancer data with strong interim findings from a phase I ...